Producción de VHH anti-vWF

• 

  Desarrollo de VHH anti-vWF eficaces

  Los científicos han utilizado otro método, las denominadas bibliotecas de visualización de fagos. Por tanto, disponen de una biblioteca de VHH conectados a pequeños virus llamados bacteriófagos. De esta forma, los científicos pueden seleccionar VHH que se unan a regiones específicas del vWF. Después de aislar y caracterizar estos Producción de VHH anti-HER2Luego, se evalúa la seguridad y eficacia de los medicamentos. El equipo de Yaohai también está trabajando con otros grupos de investigación y empresas para identificar VHH adicionales y evaluar su actividad en modelos animales hemofílicos. Esta colaboración es vital para aumentar la profundidad de la investigación.  

• 

  Investigación sobre la producción de VHH anti-vWF

  In a recent work, the scientists identified one of the most potent anti-vWF VHH and denominated it VHH-33. VHH-33 is able to effectively inhibit this process of vWF-induced platelet agglutination. In the lab and in mice with hemophilia A, it also helped break up blood clots while being relatively safe for the body — that is about as close to a rousing success as one might hope when testing therapies. Indeed, to understand how VHH-33 stops vWF and prevents its issues, the researchers examined VHH-33 more closely. 

• 

  Una nueva era en el tratamiento de la hemofilia

  There are also other research teams across the globe doing great work in this field. For instance, a team in Germany generated mouse that recognize an important part  of Bispecific VHH Production (which is essential for its binding to platelets) [21]. One of the VHHs they generated, L318, was particularly good at preventing vWF from going haywire without causing any other issues in rabbits.  

¿Por qué elegir Yaohai Anti-vWF VHH Production?

• Sistema de Calidad y Cumplimiento Normativo Global

  Yaohai BioPharma, a top 10 Microbial CDMO that integrates quality management and regulatory affairs. Our quality system that is compliant with current GMP standards as well as international regulations. Our team of regulatory experts is proficient in global regulatory frameworks to accelerate biological launches. We ensure traceable production procedures quality products, as well as conformity with the requirements of the Anti-vWF VHH Production and EU EMA. Australia TGA and China NMPA are also met. Yaohai BioPharma successfully passed an in-person audit conducted by a Qualified Person of the European Union (QP) to examine our GMP system and production facility. We also completed the initial certification audits of the ISO9001 Quality Management System and ISO14001 Environmental Management System.

• Cadena de suministro y capacidades de fabricación sólidas

  Anti-vWF VHH Production is a Top 10 biotech company specializing in microbiological fermentation. We have built a modern facility with strong RD capabilities and modern manufacturing facilities. Five production lines for pharmaceuticals in line with GMP standards for microbial purification and fermentation along with two automated fill and finish lines for vials and cartridges and pre-filled needles are available. The fermentation scales available are 100L, 500L, 1000L, to 2000L. Specifications for filling vials range from 1ml up to 25ml. the pre-filled syringes and cartridge filling specifications cover between 1-3ml. The workshop for production is cGMP compliant, and guarantees a stable supply of commercial products and clinical samples. Our factory produces large molecules that are shipped around the world.

• Experiencia profesional y amplia experiencia

  Yaohai Bio-Pharma is a leading microbial biologics CDMO. Our main focus has been the production of Anti-vWF VHH Production and therapeutics to treat pets, human and veterinary health. We have state-of-the-art RD platforms and manufacturing technology that cover the entire manufacturing process beginning with the development of microbial strains Cell banking, process and method development, through commercial and clinical manufacture that ensures the successful delivery of innovative solutions. Over time we've gained a vast knowledge of microbial-based bio processing. We have successfully completed more than 200 global projects, and help our clients with navigating the rules and regulations of the US FDA, EU EMA, Australia TGA, and China NMPA. We are able to react promptly to market demands and provide tailored CDMO services due to our experience and expertise.

• Personalización, eficiencia y rentabilidad

  Yaohai Bio-Pharma is experienced in the development of microbial-derived biologics. We offer customized RD as well as manufacturing solutions, while making sure that there are no risks. We have worked on diverse modalities such as subunit-based recombinant vaccines, Anti-vWF VHH Production, cytokines, growth factors, single domain antibodies, enzymes, plasmid DNA, the mRNA, and other. We are experts in a variety of microorganisms, including yeast extracellular and intracellular secretion (yields up to 15g/L) as well as bacteria intracellular soluble and inclusion body (yields as high as 10g/L). We have also developed the BSL-2 fermentation platform to create bacteria-based vaccines. We have a track record of improving production processes, thereby increasing yields and decreasing costs. With a highly efficient technology team, we ensure timely and quality project delivery and bring your products to market faster.

Categorías de productos relacionados

• Fabricación de plásmidos AAV
• Métodos analíticos para el ADN plásmido
• Fabricación de VLP del bacteriófago AP205
• Fabricación de VLP del bacteriófago Q
• Fabricación de vacunas VLP quiméricas
• Fabricación de vacunas VLP conjugadas
• Fabricación de vacunas de ADN
• Fermentación de E. coli para la producción de VLP
• Fabricación de agonistas de GLP-1
• Fabricación analógica GLP-1

¿No encuentras lo que estás buscando?
Póngase en contacto con nuestros consultores para obtener más productos disponibles.